Vimarsana
Biggest News Aggregation in the World

Page 2 - Intestinal Failure News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Intestinal Failure. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Intestinal Failure Today - Breaking & Trending Today

Zealand Pharma submits New Drug Application to the US FDA for glepaglutide in short bowel syndrome - Vimarsana News

Zealand Pharma submits New Drug Application to the US FDA for glepaglutide in short bowel syndrome

Press release – No. 18 / 2023 Zealand Pharma submits New Drug Application to the US FDA for glepaglutide in short bowel syndrome Copenhagen, Denmark, December 22, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for glepaglutide, a long-acting GLP-2 analog, for th

Source: yahoo.com
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q3 2023 Earnings Call Transcript - Vimarsana News

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q3 2023 Earnings Call Transcript

Operator: Thank you for standing by. My name is Aaron, and I will be your conference operator for today.

Apraglutide Reduces Parenteral Support Dependency in Patients with SBS-IF, CIC - Vimarsana News

Apraglutide Reduces Parenteral Support Dependency in Patients with SBS-IF, CIC

Final data from STARS Nutrition were presented at United European Gastroenterology Week 2023, demonstrating a significant reduction in parenteral support.

Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases - Vimarsana News

Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases

- Transaction Advances Ironwood’s Vision of Becoming the Leading GI Healthcare Company - - Adds apraglutide, Next Generation, Synthetic GLP-2 Analog in Phase 3 for Short Bowel Syndrome with... | May 22, 2023

VectivBio Reports Full Year 2022 Financial Results and Provides Business Update - Vimarsana News

VectivBio Reports Full Year 2022 Financial Results and Provides Business Update

Continued Strong Progress and Momentum Across Multiple Programs with Key Upcoming Data Milestones Beginning Q2 2023 STARS Phase 3 Program of Apraglutide in Short Bowel Syndrome with Intestinal... | April 19, 2023